AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...
As antibody–drug conjugates (ADCs) and immune checkpoint inhibitors continue to grab a lot of attention as transformative cancer therapies, they would appear to leave little room ...
The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...
Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every ...
A small genetic testing startup backed by Peter Thiel’s Founders Fund and Reddit co-founder Alexis Ohanian’s 776 Fund ...
Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...
The US Court of Appeals for the Fifth Circuit is reviving PhRMA's legal attack on Medicare drug price negotiations. On Friday ...
This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...
The US' Health Resources and Services Administration threatened Johnson & Johnson with fines for unilaterally reshaping the ...
Americans can now vaccinate themselves against the flu without the assistance of a healthcare worker.
The Federal Trade Commission said that it is suing the three major US pharmacy benefit managers over their role in the ...